Liver safety issues reported Sept. 27 in an interim analysis of the Phase III ENVISION study of Alnylam Pharmaceuticals Inc.'s RNAi therapeutic givosiran put a damper on hopes for a swift early approval and launch in acute hepatic porphyria based on a surrogate marker, but the company is pushing ahead with an accelerated attempt.
Quick Facts: Acute Hepatic Porphyria
Acute hepatic porphyrias are a family of rare, genetic diseases characterized by potentially life-threatening attacks and for many patients chronic debilitating symptoms that negatively impact daily functioning and quality of life.
Common symptoms of AHPs include severe, diffuse abdominal pain, weakness, nausea, and fatigue. Symptoms of AHPs can often resemble that of other more common conditions such as irritable bowel syndrome, appendicitis, fibromyalgia and endometriosis. Consequently, patients afflicted with an AHP are often misdiagnosed or remain undiagnosed for an average of 15 years.
Four types of AHP cause a deficiency in one of the enzymes of the heme biosynthesis pathway in the liver:
-
Acute intermittent porphyria (AIP)
Source: Alnylam
The drug is an antisense therapeutic delivered via subcutaneous injection that targets aminolevulinic acid synthase 1 (ALAS1) in the liver...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)